Current methods of making decisions on drug assets are becoming antiquated, costing a lot of time...money...and unnecessary risk. Understanding the probability of technical and regulatory success (PTRS) for a given indication enables faster, smarter decisions while minimizing risk. Learn about the new Asset Intelligence tool, which validates R&D candidates through powerful AI-driven analysis and real-world data to forecast clinical trial outcomes, in this podcast.